About Apellis Pharmaceuticals
Apellis Pharmaceuticals is a company based in Crestwood (United States) founded in 2008 by Pascal Deschatelets and Cedric Francois was acquired by Biogen in March 2026.. Apellis Pharmaceuticals has raised $213.21 million across 13 funding rounds from investors including Biogen, HHS and Eight Roads Ventures. The company has 710 employees as of December 31, 2024. Apellis Pharmaceuticals offers products and services including Complement Science Therapies and Clinical Trial Programs. Apellis Pharmaceuticals operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Crestwood, United States
- Employees 710 as on 31 Dec, 2024
- Founders Pascal Deschatelets, Cedric Francois
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Apellis Pharmaceuticals, Inc.
-
Annual Revenue
$781.37 M97.02as on Dec 31, 2024
-
Net Profit
$-197.88 M62.57as on Dec 31, 2024
-
EBITDA
$-163.18 M68.34as on Dec 31, 2024
-
Total Equity Funding
$213.21 M (USD)
in 13 rounds
-
Latest Funding Round
$328.9 M (USD), Post-IPO
May 07, 2020
-
Investors
Biogen
& 13 more
-
Employee Count
710
as on Dec 31, 2024
-
Acquired by
Biogen
(Mar 31, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Apellis Pharmaceuticals
Apellis Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol APLS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Apellis Pharmaceuticals
Apellis Pharmaceuticals offers a comprehensive portfolio of products and services, including Complement Science Therapies and Clinical Trial Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments targeting C3 for rare diseases and atrophy.
Pipeline for developing innovative disease treatments.
Unlock access to complete
Leadership Team
41 people
Software Development Team
21 people
Legal and Compliance
15 people
Senior Team
14 people
Finance and Accounting
11 people
Operations Team
9 people
Product Management Team
4 people
Sales and Marketing
3 people
Unlock access to complete
Funding Insights of Apellis Pharmaceuticals
Apellis Pharmaceuticals has successfully raised a total of $213.21M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $328.9 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Post-IPO — $328.9M
-
First Round
First Round
(01 Jul 2008)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Post-IPO - Apellis Pharmaceuticals | Valuation |
investors |
|
| Sep, 2019 | Amount | Post-IPO - Apellis Pharmaceuticals | Valuation |
investors |
|
| Aug, 2017 | Amount | Series E - Apellis Pharmaceuticals | Valuation | Sectoral |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Apellis Pharmaceuticals
Apellis Pharmaceuticals has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, HHS and Eight Roads Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sectoral Asset Management is focused on global healthcare investment.
|
Founded Year | Domain | Location | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Apellis Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Apellis Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Apellis Pharmaceuticals Comparisons
Competitors of Apellis Pharmaceuticals
Apellis Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Apellis Pharmaceuticals
Frequently Asked Questions about Apellis Pharmaceuticals
When was Apellis Pharmaceuticals founded?
Apellis Pharmaceuticals was founded in 2008.
Where is Apellis Pharmaceuticals located?
Apellis Pharmaceuticals is headquartered in Crestwood, United States.
Who is the current CEO of Apellis Pharmaceuticals?
Cedric Francois is the current CEO of Apellis Pharmaceuticals. They have also founded this company.
Is Apellis Pharmaceuticals a funded company?
Apellis Pharmaceuticals is a funded company, having raised a total of $213.21M across 13 funding rounds to date. The company's 1st funding round was a Series E of $60M, raised on Jul 01, 2008.
How many employees does Apellis Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Apellis Pharmaceuticals is 710.
What is the annual revenue of Apellis Pharmaceuticals?
Annual revenue of Apellis Pharmaceuticals is $781.37M as on Dec 31, 2024.
What does Apellis Pharmaceuticals do?
Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, United States. Therapies are developed by the company to address autoimmune and inflammatory conditions through modulation of the complement system, a key immune component. Programs are focused on ophthalmology, nephrology, hematology, and neurology, with operations centered in the biotechnology sector.
Who are the top competitors of Apellis Pharmaceuticals?
Apellis Pharmaceuticals's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
What products or services does Apellis Pharmaceuticals offer?
Apellis Pharmaceuticals offers Complement Science Therapies and Clinical Trial Programs.
Is Apellis Pharmaceuticals publicly traded?
Yes, Apellis Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol APLS.
Who are Apellis Pharmaceuticals's investors?
Apellis Pharmaceuticals has 14 investors. Key investors include Biogen, HHS, Eight Roads Ventures, Clough Capital Partners, and Sectoral Asset Management.
What is Apellis Pharmaceuticals's ticker symbol?
The ticker symbol of Apellis Pharmaceuticals is APLS on NASDAQ.